Earn rewards for your opinion on lab products.

Get exclusive insights into life science trends.

Stay up to date on research news.

How biotech startups can secure funding, according to investors
January 17, 2022 -- What are strategies that emerging biotech companies can use to attract investors and secure funding that support the development of its programs and technology? A panel of investors and finance professionals discussed the challenges and opportunities during the virtual Biotech Showcase 2022 event in a session titled "Early Seed Financing." Read More
ARM update points to strong 2022 for cell and gene therapy industry
January 14, 2022 -- Despite a turbulent investment year, the cell and gene therapy space continued to innovate and develop at an extraordinary speed, according to the "Cell & Gene State of the Industry Briefing," which was delivered on January 11 by the Alliance for Regenerative Medicine (ARM) in partnership with Biotech Showcase. Read More
CAR T cells produced in vivo may treat cardiac injury
January 13, 2022 -- New evidence suggests that immunotherapy could have the potential to temporarily reprogram patients' immune cells to attack a specific target via a single injection of mRNA. The study, published in Science, could lead to a new treatment for heart failure. Read More
Critical step identified in immune system response could lead to new treatments
January 12, 2022 -- New research has identified a crucial protein that controls the immune system's release of a key factor in fighting infections. The study, published in the journal Nature Communications on January 10, found that the MNDA protein is necessary for white blood cells to produce a type of interferon. This discovery could lead to new drugs to help fight infections or treat autoimmune conditions. Read More
How COVID-19 has shed light on importance of biotech tools, health equity
January 11, 2022 -- As the world enters the third year of the COVID-19 pandemic, it is clear that the virus has taught humanity some very tough lessons, but there have also been significant scientific advances. A panel explored the current challenges facing the industry, along with the silver linings, on January 10 at Biotech Showcase 2022. Read More
Rare disease treatments continue to advance alongside gene therapies
January 10, 2022 -- Rare diseases represent an underserved and frequently overlooked area in healthcare. As a result, funding for research in these diseases is often limited. However, many of these diseases are fatal or highly impair a patient's quality of life. According to a recent report from Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard, some institutions are focusing their efforts in the area of rare diseases. Read More
Meet and greet: SITC 2021
January 7, 2022 -- The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health. Read More
Battle royale: Self-cloaking virus vs. regenerating bacteria
January 7, 2022 -- Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human body, albeit in vastly different ways. While there may be no right or wrong answer, ScienceBoard has initiated a long-term effort to probe experts on where they would place their bets in this epic fight. Read More
Biotools M&A scene hot in 2021
January 6, 2022 -- It was a busy year for the acquisition of biotool companies. Likewise, 2022 is expected to be another busy year for lab tool mergers and acquisitions. Read More
Virtual Biotech Showcase draws over 300 life science companies
January 5, 2022 -- Biotech Showcase is an investor conference that aims to connect global life science executives with investors. The event was scheduled to take place January 10-13, 2022, in San Francisco; however, on December 16, 2021, the event's organizers announced that it would transition to a virtual on-demand platform. Read More
Scientists develop novel tools to visualize DNA repair
January 4, 2022 -- Researchers can now visualize DNA repair in unprecedented detail using a new high-throughput microscopy technique in combination with machine learning. The methodology, published in Cell Reports on December 28, has led to the identification of new proteins involved in DNA repair. Read More
New 'armed' CAR T cells can locally activate small-molecule cancer drugs
January 3, 2022 -- A new engineered CAR T platform, which turns cells into targeted “micropharmacies” with local activation of small-molecule prodrugs, has been shown to exhibit enhanced antitumor activity and can overcome a variety of current obstacles in conventional CAR T-cell therapy. The research, conducted by Memorial Sloan Kettering Cancer Center scientists, was published in Nature Chemical Biology on December 30, 2021. Read More
Gene therapy research collaborations gain traction for next-gen medicines
January 3, 2022 -- Research collaborations are becoming increasingly more common, allowing companies to pool existing resources to advance innovations in the field of medicine. There are many partnerships within the gene therapy field, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some companies engaging in such research collaborations are Regeneron, EdiGene, and Ferring Ventures. Read More
Top 10 ScienceBoard stories of 2021
December 24, 2021 -- It's been a very busy year for scientists and biotech/biomedical professionals. From COVID-19 vaccines to innovations in cell and gene therapies, the field is growing at an unprecedented pace -- with no end in sight. In 2021, ScienceBoard strived to keep our readers updated on the latest news and research in the biopharmaceutical and life sciences fields, along with insights into the people and the innovations behind notable developments. Read More
FDA authorizes Pfizer's COVID-19 pill
December 23, 2021 -- The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for nirmatrelvir and ritonavir tablets (which are co-packaged for oral use and sold under the brand name Paxlovid) for the treatment of mild to moderate COVID-19 in adults and pediatric patients (age 12 and older) who have tested positive for SARS-CoV-2 and who are at high risk of developing severe COVID-19, including hospitalization or death. Read More